Printer Friendly
The Free Library
14,736,044 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

GlaxoSmithKline K.K. to Provide Information to Medical Institutions Using Subcontracted Pharma Sales Representatives.


Tokyo, Japan, Apr 18, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
) - GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company)
GSK Glycogen Synthase Kinase
GSK Gruppentraining Sozialer Kompetenzen (Germany)
GSK Greenland Shark (FAO fish species code) 
) announced on April 17 that it has decided to implement Community MR, a subcontracting system for freelance medical sales representatives, beginning in July.

To meet that end, the company has begun recruiting candidates who have experiences in pharmaceutical sales activities. The new system allows qualified pharmaceutical sales representatives pharmaceutical sales representative Detailer, Drug rep Drug industry A drug company employee who regularly visits physicians and office practices, providing information on the company's products–usually putting a negative 'spin' on competitors' products. See Detailing.  to work on their own.

GSK will step up its drive to hire such sales representatives who have time or location constraints. Initially, the new system will cover dermatology and otology otology /otol·o·gy/ (o-tol´ah-je) the branch of medicine dealing with the ear, its anatomy, physiology, and pathology.otolog´ic

o·tol·o·gy
n.
The branch of medicine that deals with the ear.
 specialists in Tokyo's 23 wards and Yokohama as well as dispensing pharmacies in Yokohama.

Eligible candidates are those who hold an MR (medical representative) certificate, and are able to commute to the designated areas, regardless of age and gender.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Apr 19, 2006
Words:136
Previous Article:National Institute of Advanced Industrial Science and Technology (AIST) Reports Success in Continuous Synthesis of Diesel Fuel from Wood.
Next Article:Q'SAI to Launch Multi-pesticide Residue Analysis Service for Imported Foods.



Related Articles
Novartis Pharma to Spin off Its Nutrition Business in January.
Astellas Establishes New Subsidiary 'Astellas Pharma Chemicals Co., Ltd.'.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Astellas Discontinues Development of Immunosuppressant FK778.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Astellas Transfers Three European Plants to Temmler Group, German Pharmaceutical Company.
Novartis and Mochida Pharmaceutical to Co-promote Diovan in Japan.
Sumitomo Chemical Reports Consolidated Financial Results For the Nine Months Ended December 31, 2006.
Dainippon Sumitomo Pharma Announces Launch of "Replagal(R) 3.5 mg" for Anderson-Fabry Disease.
Amgen KK.(BIOTECH)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles